NewsSource: EClinCloud

CDE Seeks Comments on Antitumor Drug Clinical R&D Guidelines, Encouraging Development of eCOA/ePRO and Other Assessment Methods

4 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: eClinCloud.


Click the "blue text" above to follow us

Article illustration


Article illustration

On July 2, 2021, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) issued the "Clinical Value-Oriented Guiding Principles for Clinical Research and Development of Antitumor Drugs (Draft for Comment)", providing relatively clear guidance across multiple stages of antitumor drug development, from project initiation to clinical development.

The "Guiding Principles" note that the fundamental purpose of bringing a drug to market is to address patients' needs. It has become a broad consensus that drug R&D should place patient needs at the core and be guided by clinical value. Antitumor drug R&D, from determining the R&D direction to conducting clinical trials, should consistently uphold the principle of putting clinical needs at the center and pursue clinical value-oriented antitumor drug R&D.

It is widely believed in the industry that the purpose of issuing these "Guiding Principles" is to further emphasize the clinical value of innovative drugs and set higher requirements for innovative capabilities in new drug R&D, aiming to reduce low-level, homogeneous "pseudo-innovation" or "imitative innovation" and actively promote genuine innovative development in the pharmaceutical industry.

Notably, regarding "selection of clinical endpoints," the "Guiding Principles" for the first time propose the application of patient-reported outcome (PRO) in cancer patients and encourage applicants to develop multiple assessment methods, such as electronic PRO data collection systems (ePRO), to reduce the burden on subjects during assessments.
Article illustration

A PRO is a report coming directly from the patient regarding their own health status, functional status, and treatment experience, including measurement of symptoms, health-related quality of life, and satisfaction with treatment. PROs are often used to evaluate chronic diseases, psychiatric disorders, and diseases lacking objective indicators, as well as to understand patients' overall satisfaction with treatment.

Currently, antitumor drug R&D in China is in a stage of rapid development; new therapeutic approaches have further extended the survival of cancer patients, and malignant tumors are showing a trend toward becoming chronic conditions. This has led to higher expectations among cancer patients regarding drug safety, treatment experience, and quality of life, as well as higher expectations regarding the experience of oncology subjects in clinical trials. Proceeding from the perspective of patient needs, the "Guiding Principles" put forward recommendations for the clinical R&D of antitumor drugs.


“

The "Guiding Principles" point out that applying PROs in cancer patients can provide clinically important information that cannot be obtained from adverse event reporting; it also reflects the impact of antitumor therapy on patients, capturing patient treatment experiences and clinical benefits—as well as the impact of antitumor therapy on cancer patients' quality of life—that traditional evaluation metrics (such as OS and PFS) cannot fully capture. Applicants are encouraged to use PRO tools, such as quality of life (QoL) assessments and symptom assessments, to collect data on the effects of drug therapy on symptom relief and patients' quality of life.

”


Article illustration

From this, it can be seen that the patient-centered era has arrived. As the most widely used category of clinical outcome assessment (COA), PRO / ePRO is an important way to collect clinical data, enabling assessors to obtain more authentic and reliable information from patients and allowing clinical trials to better listen to the patient's voice.

As the exclusive strategic partner in Greater China for Signant Health, a leading global evidence-generation company, EClinCloud is responsible for all marketing and operational activities for Signant eCOA in Greater China. As a global leader in eCOA and endpoint assessment, Signant maintains a strong focus on the patient experience, consistently remaining "patient-centered" and leveraging patient engagement approaches to bring convenience to patients, benefiting countless patients.

Article illustration




EClinCloud

Guided by its mission of "bringing effective treatments to patients through technological innovation," EClinCloud is a healthcare and life sciences technology company based in China and serving the global market. Through EClinCloud's end-to-end, seamlessly integrated unified platform (including scale management, linguistic validation, study design, eCOA, eConsent, EDC, CTMS, eTMF, and more) and precision medical evaluation systems across therapeutic areas (oncology, neurology, cardiology, pulmonology, dermatology, and others), EClinCloud is building a globally leading, "patient-centric" unified SaaS cloud platform for clinical evidence support, helping well-known domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs/devices, and benefit countless patients.
Article illustration


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.